NEW YORK, August 4, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Bristol-Myers Squibb Co. (NYSE: BMY), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Pharmacyclics Inc. (NASDAQ: PCYC) and Amgen Inc. (NASDAQ: AMGN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5355-100free.
--
Bristol-Myers Squibb Co. Research Reports
On July 29, 2014, Bristol-Myers Squibb Co. (Bristol-Myers) and Pfizer Inc. (Pfizer) jointly announced that the European Commission has approved Eliquis for the treatment of DVT and PE, and the prevention of recurrent DVT and PE in adults. In addition, Eliquis is also approved in the European Union for the prevention of venous thromboembolism (VTE) in adults who have undergone elective total hip or knee replacement surgery, and for the prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors. Bristol-Myers informed that the marketing authorization for Eliquis is based on the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, and is supported by two pivotal Phase III clinical trials, AMPLIFY and AMPLIFY-EXT. The full research reports on Bristol-Myers are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/BMY/report.pdf
--
Johnson & Johnson Research Reports
On July 29, 2014, Johnson & Johnson (Johnson & Johnson) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. In addition, the FDA has approved IMBRUVICA for CLL patients with del 17p, a genetic mutation that occurs when part of chromosome 17 has been lost. IMBRUVICA is jointly developed and commercialized by Johnson & Johnson's subsidiary Janssen Biotech, Inc. and Pharmacyclics, Inc. Johnson & Johnson informed that the sNDA is based on data from the Phase III RESONATE study, which demonstrated IMBRUVICA significantly improved progression-free survival (PFS) and overall survival (OS) versus ofatumumab in patients with previously treated CLL or small lymphocytic leukemia (SLL). The full research reports on Johnson & Johnson are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/JNJ/report.pdf
--
Merck & Co., Inc. Research Reports
On July 29, 2014, Merck & Co., Inc. (Merck) released its Q2 2014 and H1 2014 financial results. The Company reported Q2 2014 sales of $10.9 billion, down 0.7% YoY. Q2 2014 net income attributable to Merck came in at $2.0 billion or $0.68 per diluted share, compared to a net income $906 million or $0.30 per diluted share in Q2 2013. Non-GAAP net income was $2.5 billion or $0.85 per share. According to analysts surveyed by Thomson Reuters I/B/E/S, the Company was expected to post Q2 2014 EPS of $0.81. H1 2014 GAAP net income attributable to Merck came in at $3.7 billion or $1.25 per diluted share, compared to a net income $2.5 billion or $0.82 per diluted share in H1 2013. For full-year 2014, the Company expects revenues in the range of $42.4 billion - $43.2 billion, and non-GAAP EPS in the range of $3.43 - $3.53 The full research reports on Merck are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/MRK/report.pdf
--
Pharmacyclics Inc. Research Reports
On July 28, 2014, Pharmacyclics Inc. (Pharmacyclics) announced that the U.S. Food and Drug Administration (FDA) has granted IMBRUVICA (ibrutinib) regular (full) approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and for the treatment of CLL patients with deletion of the short arm of chromosome 17 (del 17p CLL), including treatment naive and previously treated del 17p CLL patients. Pharmacyclics and Janssen Biotech, Inc. have jointly developed and commercialized IMBRUVICA®. The approval of IMBRUVICA® is based on data from the Phase III RESONATE™ study (PCYC-1112-CA). Pharmacyclics stated that the approval of IMBRUVICA® has prompted a milestone payment of $60 million to the Company under its collaboration agreement with Janssen Biotech, a wholly owned subsidiary of Johnson & Johnson. The full research reports on Pharmacyclics are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/PCYC/report.pdf
--
Amgen Inc. Research Reports
On July 29, 2014, Amgen Inc. (Amgen) reported Q2 2014 total revenues of $5.2 billion, up 10.7% YoY driven by strong performance across the portfolio, particularly Enbrel (etanercept), Kyprolis (carfilzomib), Prolia (denosumab) and XGEVA (denosumab). During the quarter, the Company's operating income improved 22.7% YoY to $1.9 billion. Q2 2014 GAAP net income came in at $1.5 billion or $2.01 per diluted share, compared to net income of $1.3 billion or $1.65 per diluted share in Q2 2013. For full-year 2014, the Company expects total revenues in the range of $19.5 billion - $19.7 billion and adjusted EPS in the range of $8.20 - $8.40. Amgen said that it will slash 2,400 to 2,900 jobs, primarily in the U.S., over this year and 2015 and close plants in Colorado and Washington. The full research reports on Amgen are available to download free of charge at:
http://www.analystsreview.com/Aug-04-2014/AMGN/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
